Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2017

View Archived Issues

Transfer of U.S. orphan drug designations for CAEL-101 to Caelum

Novartis exercises option to in-license ECF-843 for ophthalmic indications

U.S. breakthrough therapy designation for evinacumab in homozygous familial hypercholesterolemia

Immune-Onc collaborates with University of Texas on cancer immunotherapy

AnaptysBio initiates first-in-human trial of ANB-019

Myriad Genetics and BeiGene to develop companion diagnostics for BGB-290

Innocrin awarded second U.S. fast track designation for seviteronel

Achillion initiates phase II study of ACH-4471 in paroxysmal nocturnal hemoglobinuria

Aurinia outlines phase III plans for voclosporin in lupus nephritis

IBA Molecular and Mallinckrodt Nuclear Medicine create new company Curium

BioMed Realty and UC San Diego announce plans for new oncology research center

TRAIL receptor agonist ABBV-621 activity described for solid tumors and hematological cancers

Asceneuron cleared to begin phase I study of oral tau inhibitor ASN-120290

Envarsus, tacrolimus retard formulation, shows promise in heart transplantation

Phase III topline results on Trerief for Parkinsonism accompanying DLB

BioTime establishes AgeX Therapeutics subsidiary

Quiet Therapeutics describes tumor targeting with hyaluronic acid-coated lipid nanoparticles

Nanobiotix completes private placement of shares to support progress with NBTXR-3

Novel HIF-1 inhibitor, IDF-11774, suppresses tumor growth through regulation of cancer metabolism

Hefei PreceDo Pharmaceuticals discovers novel FLT-3 inhibitors

XW Laboratories patents gamma-hydroxybutyric acid prodrugs

Zhejiang Bossan Pharmaceutical describes new EGFR inhibitors

GlaxoSmithKline divulges novel anti-HIV compounds

Indiana University Research and Technology, Assembly Biosciences present HBV core protein modulators

Neuropilin-2 identified as a marker of prostate cancer-specific survival

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...